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Heparan sulfates (HSs) are key components of mammalian cells surface and extracellular
matrix. Structure and composition of HS, generated by HS-biosynthetic system through
non-template-driven process, are significantly altered in cancer tissues. The aim of this
study was to investigate the involvement of HS-metabolic machinery in prostate carcino-
genesis. Transcriptional patterns of HS-metabolic enzymes (EXT1, EXT2, NDST1, NDST2,
GLCE, 3OST1/HS3ST1, SULF1, SULF2, HPSE) were determined in normal, benign, and
cancer human prostate tissues and cell lines (PNT2, LNCaP, PC3, DU145). Stability of the
HS-metabolic system patterns under the pressure of external or internal stimuli was stud-
ied. Overall impairment of transcriptional activity of HS-metabolic machinery was detected
in benign prostate hyperplasia, while both significant decrease in the transcriptional activity
and changes in the expression patterns of HS metabolism-involved genes were observed in
prostate tumors. Prostate cancer cell lines possessed specific transcriptional patterns of HS
metabolism-involved genes; however, expression activity of the system was similar to that
of normal prostate PNT2 cells. HS-metabolic system was able to dynamically react to differ-
ent external or internal stimuli in a cell type-dependent manner. LNCaP cells were sensitive
to the external stimuli (5-aza-deoxycytidin or Trichostatin A treatments; co-cultivation with
human fibroblasts), whereas PC3 cells almost did not respond to the treatments. Ectopic
GLCE over-expression resulted in transcriptional activation of HS-biosynthetic machinery in
both cell lines, suggesting an existence of a self-regulating mechanism for the coordinated
transcription of HS metabolism-involved genes.Taken together, these findings demonstrate
impairment of HS-metabolic system in prostate tumors in vivo but not in prostate cancer
cells in vitro, and suggest that as a potential microenvironmental biomarker for prostate
cancer diagnostics and treatment.
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INTRODUCTION
Heparan sulfate proteoglycans (HSPGs) play an important role in
cell–cell and cell–matrix communication and signaling, being an
essential part of the cell microenvironment (1, 2). A functional
specificity of interactions of heparan sulfate (HS) with multiple
cell surface and extracellular ligands is related to the fine struc-
ture of the HS polysaccharide chains, generated by the system
of HS-synthesizing and modifying enzymes (3, 4). Because of
non-template nature of HS biosynthesis, functional capabilities
of the HS-metabolic machinery is vital for proper HS synthesis
and functions, and understanding of HS biosynthesis regulation
is important for the understanding of the HSPGs functions (5–7).
During carcinogenesis, significant changes in HS structure,
composition, and functional activity occur (8–11), and distortion
of the HS-biosynthetic machinery could be a first candidate for the
changes. Many different enzymes (multiple glycosyltransferases,
sulfotransferases, and an epimerase) participate in HS biosyn-
thesis and catalyze the assembly and modification of HS chains
(12, 13). All the enzymes work together and each participant pro-
vides the preferred substrate for the next reaction in the pathway,
forming highly informative HS chains. A physical complex of the
enzymes, committed to the assembly of HS, was designated as
“GAGosome” (14, 15).
Recently, a direct involvement of individual HS-metabolic
enzymes in carcinogenesis was demonstrated, although for some
enzymes the obtained data are still controversial. Potential tumor-
suppressor function is shown for EXT1,NDST4,GLCE,and SULF1
genes and changes of their expression were detected in different
human tumors: EXT1 is epigenetically inactivated in leukemia
and non-melanoma skin human primary tumors and cell lines
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(16) and mutationally inactivated in solid osteochondromas (17),
but EXT1 expression is associated with bad prognosis in multiple
myeloma cells (18); NDST4 is a novel candidate tumor-suppressor
gene, and the loss of its function might be involved in colorectal
cancer progression (19); GLCE is down-regulated in both breast
primary tumors and cell lines (20, 21) and lung cancer cell lines
(22), although GLCE up-regulation correlates with aggressive dis-
ease in prostate cancer (23, 24); SULF1 is epigenetically silenced
in ovarian cancer cell lines and primary tumors (25); in contrast
to the tumor-suppressor effect of SULF1, SULF2 expression pro-
motes hepatocellular carcinoma cell growth in vitro and in vivo
(26); SULF2 is up-regulated in NSCLC and other cancers and
implicated as a driver of carcinogenesis in NSCLC, pancreatic can-
cer, and hepatocellular carcinoma (27); enhanced heparanase-1
expression correlates with poor prognosis in most of the cancers
in which it has been examined, and over-expression and knockout
studies clearly implicate the heparanase as a master regulator of
cancer progression and metastasis (28, 29). All the results support
an involvement of HS-metabolic enzymes in carcinogenesis and
show complex changes of their expression levels in tumors.
Till date, only few studies were performed to reveal transcrip-
tional patterns for HS-metabolic machinery in normal and cancer
tissues. Complex characterization of expression profiles of 100
genes, involved in synthesis of glycosaminoglycan (GAG) chains,
was done for normal and malignant human plasma cells using
Affymetrix microarray. It was shown that expression of nine of
these genes – EXT2, CHSY3, CSGALNACT1, HS3ST2, HS2ST1,
CHST11, CSGALNACT2, HPSE, SULF2 – are significantly differ-
ent between normal and malignant plasma cells (17). Expression
analysis of a set of 419 functionally relevant genes involved in
synthesis, degradation, and binding of N-linked and O-linked
glycans, Lewis antigens, GAGs (chondroitin, heparin, and ker-
atan sulfate in addition to hyaluronan) and glycosphingolipids
revealed that mRNA levels for many of them differ significantly
between normal and malignant breast tissue (30). Transcriptomic
and histochemical approaches were used to analyze the expres-
sion of the enzymes involved in HS and chondroitin sulfate (CS)
biosynthesis and editing, as well as the proteoglycan core pro-
teins, in metastatic and non-metastatic breast adenocarcinomas.
No significant change in transcription was detected in approxi-
mately 70% of analyzed genes, however, 13 genes demonstrated
changes in both tumor types (syndecan-1, glypican-3, perlecan,
NDST4, 3-O-sulfotransferase) and 5 genes showed changes only
in non-metastatic tumors (sulfatases), expression of heparanase-2
but not heparanase-1 was significantly deregulated (31). Expres-
sion of nine HS-modifying enzymes (HPSE, 2OST1, 3OST1,
3OST3B, 6OST1, NDST1 and 2, Sulf1 and 2) was heteroge-
neously changed in human fibrogenic diseases and hepatocellular
carcinoma, with intensified expression of several HS-modifying
enzymes (NDST1 and -2, 3OST1, Sulf1) in pathological tissues
(32). A study on the expression of HS-synthesizing enzymes in
the development of Nematostella vectensis shows that the expres-
sion levels of EXT1, EXT2, NDSTa, NDSTb, C5 epimerase, and
2OSTa are rather uniform at all stages, but 6OST, 3OST, and
Sulf display elevated expression levels during blastula and gas-
trula stages (33). The expression of HS sulfotransferases (3-O-
sulfotransferase-1 [3OST1], -2, and -4; 6OST1, -2, and -3; and
N -deacetylase/N -sulfotransferase-1 [NDST1], -2, and -3) is spa-
tiotemporally regulated in the development of the nervous system,
suggesting spatiotemporal changes of the HS structure and vari-
ous biological activities in the developing mouse brain (34). At the
moment, it is almost all publications in this field.
The results suggest a hypothesis that not only expression levels
of individual enzymes but also their ratio and functional balance
are of importance in successfully working HS-metabolic system.
These individual changes seem to disbalance HS metabolism and
create cancer-specific transcriptional patterns of HS-metabolic
system in cancer tissues.
In this study, we investigated the common expression patterns
of key HS metabolism-involved genes in normal, benign, and can-
cer human prostate tissues and cell lines. Stability of the system
upon different external or internal stimuli was studied as a possi-
ble molecular mechanism of dynamic HS structure/composition
changes in prostate cancer.
MATERIALS AND METHODS
PATIENTS AND TISSUE SAMPLES
All tissue samples were obtained from primary tumors during
radical surgery at the Central Municipal Hospital N1, Novosi-
birsk, Russia. Tissues were “snap-frozen” in liquid nitrogen and
stored at –70°C. Regions were manually dissected from the frozen
blocks to provide a consistent tumor cell content of more than
70% for analysis. The majority of prostate cancer patients were
at the II–III stage of malignancy progression according the TNM
staging system. PSA was 0.1–8.5 ng/ml for BPH and 1.8–50 ng/ml
for adenocarcinoma patients, Gleason scores were 2–9. Normal
prostate tissue samples were obtained from normal prostates surgi-
cally resected by medical indications during non-prostate surgery.
All patients provided written informed consent and the study pro-
tocol was approved by the Local Ethics Committee in accordance
with the Helsinki Declaration of 1975.
ANALYSIS OF HS METABOLISM-INVOLVED GENES EXPRESSION USING
RT-PCR
Total RNA was extracted from the cells using the PureLink Total
RNA Purification System (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. cDNA was synthesized
from 1 to 2µg of total RNA using a First Strand cDNA Synthesis
kit (Fermentas, Hanover, MD, USA) and 1/10th of the product was
subjected to PCR analysis.
The following conditions were used for RT-PCR: 95°C for
10 min, 95°C for 15 s, 55–64°C for 15 s, and 72°C for 1 min, with
a final elongation step at 72°C for 10 min using a Tercik PCR
machine (DNA-Technology, Russia). The total reaction volume
was 20µl. The amplified products were separated on 1.2% agarose
gels. The gels were scanned using the “DNA Analyzer” system
(Moscow, Russia) and genes expression levels were estimated from
the intensity of the amplified DNA fragment normalized against
the intensity of GAPDH.
The PCR primers and conditions are listed in Table 1.
CELL LINES, CELL CULTURE, AND 5-aza-dC/TSA TREATMENT
The PNT2 normal human prostate epithelial cell line was obtained
from the European Collection of Cell Cultures (ECACC, Salis-
bury, UK). The human immortalized fibroblasts, LNCaP, PC3, and
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Table 1 | Primer sequences and PCR conditions.
Gene Sequences DNA product, bp PCR conditions
AnnealingT, °C Cycles
EXT1 F 5’-TTGGGTCCTTCAGATTCCTG-3’ 329 59 33
R 5’-TCCTCCAGGATGTTTGTTCC-3’
EXT2 F 5’-AAGCACCAGGTCTTCGATTACC-3’ 296 55 33
R 5’-GAAGTACGCTTCCCAGAACCA-3’
NDST1 F 5’-CACACAGAACGAACTACGC-3’ 513 64 33
R 5’-CCCGTTGATGATCTTGTCC-3’
NDST2 F 5’-GCCTCCAGTTCCACCTC-3’ 575 64 33
R 5’-CGACGAAGAACTGGTCC-3’
GLCE F 5’-CTACACAATGGGGACCTCAAGGC-3’ 665 59 34
R 5’-GCCACCTTTCTCATCCTGGTTCC-3’
3-OST1 F 5’-CGGGTCTCAGTGGGTGCCTG-3’ 382 64 33
R 5’-ATCCTGGAGGGTCCCCGCTT-3’
SULF1 F 5’-CTCACAGTCCGGCAGAGCAC-3’ 371 59 33
R 5’-CACGGCGTTGCTGCTATCTGC-3’
SULF2 F 5’-GAGGCAGATTCACGTCGTTTCCA-3’ 302 59 33
R 5’-ATCTGGTGCTTCTTTTGGGATGCGGGAG-3’
HPSE F 5’-TTCGATCCCAAGAAGGAATC-3’ 720 59 33
R 5’-ATAAAGCCAGCTGCAAAGGT-3’
GAPDH F 5’-GGGCGCCTGGTCACCAG-3’ 350 59 22
R 5’-AACATGGGGGCATCAGCAGAG-3’
DU145 cell lines were obtained from MTC (Karolinska Institute,
Sweden). The cell lines were maintained in RPMI medium sup-
plemented with l-glutamine, 100 units/ml penicillin, 100µg/ml
streptomycin, and 10% FBS at 37°C in a humidified 5% CO2
incubator. Treatment with deoxyazacytidine (5-aza-dC 2µg/ml)
or Trichostatin A (TSA, 250 ng/ml) was performed by incubat-
ing the cells with the drugs for 72 or 24 h, respectively. Cells were
harvested using trypsin/EDTA.
TRANSFECTION AND SELECTION OF STABLE CELL CLONES
To obtain stable LNCaP and PC3 cell clones expressing GLCE,
epi-pCEP4 plasmid was used (21). Transfection and selection
of stable cell clones were performed as described earlier (24).
Briefly, LNCaP and PC3 cells were transfected with epi-pCEP4 or
pCEP4 plasmid DNA (0.5µg DNA per well) in 12-well plates using
Lipofectamine and Plus Reagent (Invitrogen, USA) according to
the manufacturer’s protocol. Transiently transfected epi-LNCaP,
pCEP4-LNCaP and epi-PC3, pCEP4-PC3 cells were cultured for
2–3 weeks in RPMI medium containing Hygromycin (400µg/ml)
to select stable clones.
ANALYSIS OF GLCE EXPRESSION USING MULTIPLEX RT-PCR
Multiplex RT-PCR analysis of GLCE expression was per-
formed as previously described (24). Total RNA was
extracted using the PureLink Total RNA Purification Sys-
tem (Invitrogen), cDNA was synthesized using a First
Strand cDNA Synthesis kit (Fermentas). The PCR primers
used were: GLCE-F, 5’-AAGGGAGACGAGAGGGGAACGAA-3’;
GLCE-R, 5’-GCCACCTTTCTCATCCTGGTTC-3’; GAPDH-F, 5’-
GGGCGCCTGGTCACAA-3’; GAPDH-R,5’-AACATGGGGGCAT
CAGCAGA-3’.
IMMUNOSTAINING
For immunohistochemistry, 3- to 3.5-µm sections of formalin-
fixed, paraffin-embedded tissue sections were deparaffinized and
antigen was retrieved by treatment with unmasking solution at
95–98°C for 20 min. Immunostaining was performed using biotin-
free polyvalent DAB system (Spring Bioscience, USA) according
to the manufacturer’s instructions. Briefly, endogenous peroxi-
dase was blocked by incubation with peroxidase inhibitor (30 min
at 37°C), unspecific staining was blocked with 5% Fetal Bovine
Serum in PBS (20 min at 37°C), and the primary anti-HS mouse
monoclonal antibody (Abnova, USA) (1:200) and secondary anti-
mouse HRP (1:2000) were used for immunostaining (1 h at 37°C).
Staining patterns were visualized by incubation with DAB (15 min
at 37°C), counterstained with hematoxylin–eosin, and observed
by light microscopy (Axiostar Plus, Carl Zeiss).
STATISTICAL ANALYSIS
Statistical analyses were performed using a computer program
ORIGIN Pro 8.1; a value of p< 0.05 was considered to indi-
cate a statistically significant difference. Data are expressed as the
means± SEM. Differences between the means of three different
groups of patients were analyzed using ANOVA.
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RESULTS
HEPARAN SULFATE EXPRESSION IN NORMAL AND PATHOLOGICAL
HUMAN PROSTATE TISSUES
Heparan sulfate expression in normal human prostate tissue
and prostate tumors was determined using immunohistochemical
staining with anti-HS mouse monoclonal antibody (Figure 1).
The obtained results show that HS expression is changed in
prostate tumors compared with the normal human prostate tissue
mainly due to decreased HS content in tissue stroma and heteroge-
neous HS expression in different cells/tissue compartments even
within the same prostate cancer specimen (Figure 1).
Because of non-template-driven HS biosynthesis, HS-
metabolic machinery and transcriptional disbalance of a number
of HS biosynthesis/modification-involved genes could be the first
potential candidate for the observed heterogeneity of HS expres-
sion in prostate tumors. To test the hypothesis, we have selected
a list of nine key genes for HS metabolism, involved in both syn-
thesis and modification/degradation of HS chains (EXT1, EXT2,
NDST1, NDST2, GLCE, OST1/HS3ST1, SULF1, SULF2, HPSE)
(Figure 2A).
HEPARAN SULFATE BIOSYNTHESIS IS IMPAIRED IN BPH AND
PROSTATE CANCER TISSUES
RT-PCR analysis was used to study expression of all the genes in
clinical specimens of normal prostate tissue, BPH, and prostate
tumors. Specific primers and PCR conditions are listed in Table 1.
Expression level of each gene was determined from the intensity
of the amplified DNA fragments normalized to that of GAPDH
and plotted onto graph (Figure 2B).
According to the RT-PCR data, the overall activity of HS-
metabolic machinery both in BPH and prostate tumors was sig-
nificantly lower than that in normal prostate tissue (ANOVA,
Sig. 0.00007). However, specific transcriptional patterns of HS
metabolism-involved genes were shown in BPH and prostate can-
cer tissues (Figures 2B,C). While all the genes, except NDST2,
were expressed in relatively balanced ratio in normal and BPH
specimens, disbalance of the transcriptional patterns in favor
to HS chains elongation stage (EXT1/EXT2) was observed in
prostate tumors, where total expression level of EXT1 and
EXT2 expression constituted near a half of the total enzymes
expression.
The obtained results clearly show that transcriptional activ-
ity of HS-metabolic system is impaired by two to three times in
pathological prostate tissues, and BPH and prostate tumors possess
different expression patterns of HS biosynthesis/modification-
involved genes. Heterogeneity of prostate tumors on this para-
meter could result from an existence of cancer cell sub-types with
different activity of HS-metabolic system, contributing to high
intratumor heterogeneity in prostate cancer.
PROSTATE CANCER CELLS LNCaP, PC3, AND DU145 HAVE DIFFERENT
TRANSCRIPTIONAL PATTERNS OF HS-METABOLIC SYSTEM
To study a possible heterogeneity of prostate cancer cells in terms
of HS metabolism activity further, transcriptional patterns of HS-
metabolic enzymes were determined in morphophysiologically
different prostate cancer cell lines in vitro. Hormone-dependent
non-metastatic cell line LNCaP, hormone-independent metastatic
cell lines PC3 and DU145, and normal prostate cells PNT2 were
used in this experiment (Figure 3).
The expression pattern of the genes in normal prostate epithe-
lial cells, PNT2, were most balanced, with comparable contribu-
tion of each gene into common transcriptional activity of HS-
metabolic system. However, there was a significant difference in
the patterns between the LNCaP, PC3, and DU145 cancer cell lines
(Figures 3B,C). Overall expression levels of the genes in different
cancer cells were both lower (LNCaP), similar (PC3), or higher
(DU145) than in PNT2 cells, up to twofold difference between
LNCaP and DU145 cells. These quantitative changes in transcrip-
tional activity of HS-metabolic machinery were accompanied by
qualitative changes in the composition and ratio of the differ-
ent genes expressed in the cells. The cell lines were different in
terms of relative contribution of HS chain elongation (EXT1/2)
and modification (NDST1/2, GLCE, OST1, SULF1/2) stages. If
“elongation-related” genes were more actively transcribed in PC3
cells, “modification-related” genes showed higher total expression
level in DU145 cells (Figure 3).
FIGURE 1 | Immunocytochemical analysis of heparan sulfate
expression in normal human prostate and prostate cancer tissues. An
anti-HS monoclonal antibody (Abcam) were used; normal
prostate – epithelial prostate cancer cells and extracellular matrix are
stained (brown); prostate cancer – two images from the same prostate
tumor show a heterogeneity of HS expression (high and low HS expression
in morphologically different epithelial prostate cancer cells are shown on the
left and right images, respectively), low HS expression in extracellular matrix
is shown (light brown); representative prostate cancer specimen is
presented; magnification ×200.
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FIGURE 2 |Transcriptional patterns of HS-synthetic enzymes in normal
human prostate tissue, benign prostate hyperplasia, and prostate
tumors. (A) Schematic organization of the HS-biosynthetic machinery.
(B) Comparative analysis of relative transcription activity of key genes
involved in HS biosynthesis, 1–16-patients. (C) Relative activity of
HS-metabolic machinery in normal prostate tissue, BPH, and prostate tumors.
Stacked column compares the contribution of each value to a total across
categories. BPH, benign prostate hyperplasia.
In summary, the results show that LNCaP, PC3, and DU145
prostate cancer cell lines differ in the transcriptional activity and
specific patterns of HS-metabolic system. However, no impair-
ment of HS-metabolic system in prostate cancer cells was observed
compared with the normal prostate PNT2 cells in vitro.
HS-METABOLIC SYSTEM IS DYNAMICALLY REGULATED BY DIFFERENT
EXTERNAL AND INTERNAL STIMULI IN CELL TYPE-DEPENDENT
MANNER
However, to exclude the possibility that the average 30–40% differ-
ences in transcriptional activity of HS-metabolic system between
the cell lines might result from physiological variations of the cells
states, an ability of the system to dynamically react to different
external or internal stimuli was studied. LNCaP and PC3 cells were
treated with chemical drugs (5-deoxyazacytidine or Trichostatin
A), underwent the internal activation of one of the system mem-
bers (GLCE) or co-cultivation with another cell type (fibroblasts)
(Figure 4).
GLCE–LNCaP and GLCE–PC3 stable clones were used for the
experiment, GLCE up-regulation in the clones was confirmed by
multiplex RT-PCR, the presence of GLCE protein was verified by
immunocytochemical staining (23). In the co-culture experiment,
prostate cancer cells and fibroblasts were cultivated together with a
starting ratio 1:1 for 48–72 h. After co-cultivation, LNCaP or PC3
prostate cancer cells and fibroblasts were separated using magnetic
separation system (Miltenyi Biotec). Transcriptional patterns of
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FIGURE 3 |Transcriptional patterns of HS-metabolic enzymes in
different prostate cancer cell lines. (A) Representative gels
showing the expression levels of HS metabolism-involved genes
amplified by RT-PCR. (B)Transcription patterns of HS-biosynthetic
machinery in the cell lines. Stacked column compares the
contribution of each gene to an overall expression pattern across
categories. (C) Expressions of key HS-metabolic enzymes in normal
and cancer human prostate cells. The genes expression levels
normalized to that of GAPDH. Bars represent the mean±SD from
triplicate experiments (OriginPro 8.1).
key HS-metabolic machinery were determined in LNCaP and PC3
prostate cancer cells by RT-PCR before and after the treatments
(Figure 5). Twofold differences were taken as significant.
According to the obtained results, HS-metabolic system is able
to dynamically react to different external or internal stimuli in cell
type-dependent manner.
LNCaP cells were specifically affected by the treatments –
TSA or fibroblasts co-cultivation did not change the levels of
transcriptional activity of HS metabolism-involved genes but re-
balanced it toward post-synthetic editing of HS structure (TSA)
or NDST1/2 up-regulation (fibroblasts co-cultivation), while the
5-aza-dC treatment and ectopic expression of GLCE resulted
in 50% and twofold overall activation of HS-metabolic system,
respectively.
PC3 cells were much less sensitive to the applied stimuli and
all fluctuations in the expression levels lay within the 25–30%
interval. Only ectopic expression of GLCE was able to activate HS
biosynthetic machinery up to 1.5–2-fold.
In general, internal up-regulation of one of the HS metabolism-
involved genes (GLCE) had the most prominent effect on over-
all transcriptional activation of other genes in the machinery,
suggesting an existence of feedback mechanism for the con-
trol of coordinated expression of HS-metabolic system as a
whole.
Taken together, the results show decreased transcriptional activ-
ity and different expression patterns of HS-metabolic machin-
ery in human BPH and prostate cancer tissues in vivo. Specific
transcriptional patterns of HS metabolism-involved genes are
shown also for different prostate cancer cell lines (LNCaP, PC3,
and DU145). Androgen-dependent non-metastatic LNCaP cells
and androgen-independent metastatic PC3 cells differ on their
ability to dynamically react to the different external stimuli (5-
deoxyazacytidine or Trichostatin A treatments, co-cultivation with
fibroblasts) – LNCaP cells are sensitive to the stimuli, whereas
PC3 cells are not. Only ectopic GLCE over-expression acti-
vates transcription of HS-metabolic system in both LNCaP and
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FIGURE 4 | Schematic representation for the experiment on
stability/instability of the expression patterns of HS-metabolic enzymes
in prostate cancer cells. LNCaP and PC3 prostate cancer cells were used,
5-aza-dC – 5-deoxyazacytidine, multiplex RT-PCR gel showing GLCE
expression in LNCaP and PC3 cells stably transfected with the pCEP4 or
GLCE–pCEP4 plasmids (GLCE-LNCaP, GLCE–PC3) is presented.
PC3 cell lines, suggesting internal up-regulation of one of the
HS-biosynthetic machinery-involved genes as the most effective
way for activation of HS-metabolic system in prostate cancer
cells.
DISCUSSION
In this study, a complex approach to investigation of transcrip-
tional activity of HS-metabolic system in normal and pathological
prostate tissues was applied. However, the obtained results on
the impairment of expression of HS-metabolic genes in BPH
and prostate tumors (Figure 2) need a careful interpretation
due to complex nature of prostate tissue and presence of other
cell types contributing into common expression profiles of HS
metabolism-related genes.
Comparative analysis of the expression data for prostate tis-
sue samples (Figure 2) and all epithelial prostate cancer cell
lines (Figure 3) shows a similar expression activity of HS-
metabolic system in cancer tissues in vivo and prostate epithe-
lial cancer cells in vitro. However, normal prostate epithelial
cells, PNT2, also have a similar activity, which is threefold
lower than that of normal prostate tissue in vivo (Figures 2,3),
suggesting an important contribution by other tissue compo-
nents like fibroblasts, lymphocytes, macrophages, etc to overall
expression pattern of HS metabolism-related genes in normal
prostate tissue in vivo. Possibly, stromal fibroblasts are the main
source for extracellular proteoglycans in normal tissue, and an
impaired expression of HS metabolism-involved genes in prostate
cancer-associated fibroblasts (CAFs) significantly contributes to
the overall impairment of HS-biosynthetic system in prostate
tumors. Several other studies show inhibition of production of
extracellular matrix (ECM) components by CAFs. For example,
an expression of collagens I, II, III, IV, fibromodulin, and pro-
teoglycans (decorin, biglycan, lumican) in stromal cells, when
grown in the presence of two metastatic prostate cancer cell lines
PC3 and DU145, is significantly down-regulated (35). Down-
regulation of procollagens I, III, IV, fibronectin, and CS pro-
teoglycans (5–10-fold) are detected in tumorigenic NbF-1 cells
versus non-tumorigenic NbF-1 cultures (36). Close metabolic
cooperation between fibroblast and epithelial cells, involving the
production of growth factors by the epithelial cells and the
production of extracellular matrices and growth factors by the
fibroblasts, is important in promoting prostate tumor growth
in vivo (37). The results of the present study are consistent with
the data on decreased expression of the main protein compo-
nents of ECM by CAFs, and extend those with parallel impair-
ment of biosynthetic machinery for polysaccharide parts of the
proteoglycans.
Interestingly, the overall inhibition of HS-metabolic system in
prostate cancer is realized through the coordinated changes in
the expression levels of all HS metabolism-involved genes but
not at the expense of an individual one. The results fit well with
GAGosome concept, where HS biosynthesis is driven by a phys-
ical complex of interacting enzymes. For example, EXT1 and
EXT2 form a hetero-oligomeric complex in vivo that leads to
the accumulation of both proteins in the Golgi apparatus (38);
EXT1 and EXT2 affect the amount of NDST1 present in the cell,
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FIGURE 5 | Stability of HS-metabolic system upon different
external and internal stimuli. (A) Expressions of key HS
metabolism-involved genes in LNCaP and PC3 prostate cancer cells
before and after the treatments with 5-aza-deoxycytidine (+5-aza-dC),
Trichostatin A (+TSA), ectopic over-expression of GLCE (+GLCE),
co-culture with human fibroblasts (+fibroblasts). The genes
expression levels normalized to that of GAPDH. The graphs show the
mean expression levels from triplicate experiments (±s.d.) (OriginPro
8.1). Genes up-regulated or down-regulated >2-fold are shown.
(B) Relative activity of HS-metabolic machinery before and after the
treatments. Stacked column compares the contribution of each value
to a total across categories.
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which, in turn, greatly influences HS structure, and there is a
direct physical interaction between EXT2 and NDST1 (10); low-
ered expression of NDST1 results in a higher sulfate content of
heparin synthesized (11); Hsepi forms a complex with Hs2st and
Hs6st in S2 cells, raising the possibility that this complex for-
mation contributes to the close functional relationships between
these enzymes (39). Biosynthetic activity of the GAGosome is
tightly associated with physiological properties of the cells: stromal
Ext1-levels modulate tumor cell proliferation and affect the inter-
stitial fluid pressure in a 3-D spheroid model (40); Ext1 mutant
fibroblasts displayed reduced ability to attach to collagen I and to
contract collagen lattices, decreased phosphorylation of ERK1/2
in response to FGF2 stimulation (whereas neither PDGF-BB nor
FGF10 signaling was significantly affected), and reintroduction of
Ext1 rescued HS chain length, FGF2 signaling, and the ability of
the fibroblasts to contract collagen (41); EXTL2 functions to sup-
press GAG biosynthesis that is enhanced by a xylose kinase and
the EXTL2-dependent mechanism that regulates GAG biosynthe-
sis might be a “quality control system” for proteoglycans (42).
The results of the present study stay in line with the concept of
GAGosome as a functional enzymatic system, and show that the
system seems to be coordinately regulated at the transcriptional
level.
These results are supported by in vitro experiments on sensi-
tivity of the transcriptional patterns of HS metabolism-involved
genes to different external or internal stimuli. The balanced activa-
tion of HS-biosynthetic machinery in prostate cancer cells upon
the ectopic over-expression of GLCE (Figure 5B) was evidently
more profound than an influence of chemical drugs or presence
of other cell types alongside. An independent effect for LNCaP
and PC3 cell lines support an existence of a special molecular
mechanism tightly controlling overall transcriptional balance of
HS-metabolic machinery, possibly through its regulation as a sin-
gle transcriptional group or/and with a positive/negative feedback
regulation by HS structure.
The regulation seems to still work in LNCaP cell line, in spite
of the decreased overall transcriptional activity of HS-metabolic
system in the cells, and deregulated in more aggressive androgen-
independent metastatic PC3 cells, which almost lose the ability to
respond to the stimuli (Figure 5).
Possibly, the ability of HS-metabolic machinery to react dynam-
ically to external stimuli is physiologically normal and vital, and the
main problem could be insensitivity to microenvironmental influ-
ences rather than physiological fluctuations in HS-biosynthetic
system activity. Developmental data are good points in favor of
the hypothesis. Changes in activity of HS-biosynthetic machin-
ery are shown during developmental process, when some enzymes
are activated and other inactivated during development, creat-
ing developmentally appropriate HS structures (33, 34). These
changes may be regulated via unknown yet molecular mechanism,
possibly involving a feedback through the structure of cell surface
and ECM proteoglycans. Additional studies are necessary in this
field.
Taken together, the results of the present study strongly suggest
that HS-metabolic system is involved in prostate carcinogenesis,
and may be a promising target for prostate cancers diagnosis and
treatment.
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